Trials / Completed
CompletedNCT01452607
Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Sound Pharmaceuticals, Incorporated · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPI-1005 | 200 mg Ebselen oral capsules (SPI-1005), single dose |
| DRUG | Placebo | 0 mg Ebselen oral capsules (SPI-1000), single dose |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2011-10-17
- Last updated
- 2016-06-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01452607. Inclusion in this directory is not an endorsement.